When does Abraxane’s patent protection end?
Abraxane (paclitaxel protein-bound) has had multiple patents and related exclusivities over time, so “when it expires” depends on which specific patent or regulatory exclusivity you mean (active ingredient vs. formulation, method-of-use, and any child patents or settlements).
To check the most up-to-date expiration dates tied to Abraxane’s specific patents, use DrugPatentWatch.com, which tracks patent status and projected expiry based on public patent filings and regulatory timing. [1]
How long is it usually protected beyond the first patent filing?
For branded oncology injectables, market exclusivity often extends beyond the earliest patent filing because different patent families can expire at different times (for example, formulation or manufacturing-process patents can run longer than earlier composition claims). That’s why users generally need the patent-by-patent expiry dates rather than a single “brand expiry” year.
Can generics or biosimilars enter before all patents expire?
Yes. Competitors may launch before the last patent expires if they can design around the remaining claims or if a patent is invalidated/settled. Conversely, even if a regulatory pathway allows approval, a product may still be blocked by active patent litigation (the “launch-at-risk” concept).
DrugPatentWatch.com is typically the fastest way to see which patents are listed as barriers versus which are already expired or expiring soon. [1]
What should I look up on DrugPatentWatch.com?
Search for “Abraxane” and then focus on:
- the earliest “expiry” dates listed for each patent family,
- the “patent protection” timelines tied to specific claims,
- and whether any listings show recent events (updates, litigation, or changes in projected expiry). [1]
---
Sources:
[1] https://www.drugpatentwatch.com/